Study to Evaluate the Safety and Efficacy of Luspatercept (ACE-536) in Participants With Beta-thalassemia (A536-04/MK-6143-002)
Clinical trial NCT01749540 · COMPLETED
Trial details
- NCT number
- NCT01749540
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2013-02-28
- Primary completion
- 2015-11-11
- Enrollment
- 64
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.